Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Long-term Debt
Borrowings due after more than one year.
Maze Therapeutics, Inc.NASDAQ: MAZE
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt remains negative
Q1 FY2026 long-term debt was $38.83M, compared with $0 a year earlier.
Context
- Long-term debt amounted to 9.3% of total assets at the end of Q1 FY2026, up 9.3 pp from a year earlier.
- Long-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 20.08M | — |
| FY2022 | 2022-12-31 | 0 | — |
Long-term Debt vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
- Long-term debt amounts to 9.3% of total assets for MAZE, versus a peer median of 10.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $609.84M USD | +95.9% | -6.0% | 71.9% | |
| Jun 2026 | $535.52M USD | +87.2% | +17.2% | 16.5% | |
| Mar 2026 | $203.52M USD | +34.5% | — | 40.3% | |
| Mar 2026 | $38.83M USD | — | — | 9.3% | |
| Dec 2025 | €24.77M EUR | -46.5% | -0.9% | 10.0% | |
SEPNSepterna, Inc. | Sep 2026 | $19.48M USD | — | — | 3.1% |
BIOABioAge Labs, Inc. | Mar 2026 | $2.23M USD | +111.1% | +1.1% | 0.6% |
| Mar 2026 | $97K USD | — | — | 0.2% | |
| Peer median (excluding MAZE) | — | +87.2% | +0.1% | 10.0% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.